Thursday, June 4, 2026 8:00 AM – 5:30 PM EST
Friday, June 5, 2026 8:00 AM – 1:00 PM EST
Virtual & In-person
Day 1 – June 4, 2026
Welcome and Opening Remarks
8:00 AM – 8:15 AM | Kevin Gray, M.D.
Integrating Psychiatry into Pediatric Primary Care
8:15 AM – 9:15 AM | Rachel Getzenberg, M.D. | 1.0 CE credit
About the Session: The Collaborative Care (CC) model is an evidenced-based method of treating behavioral health conditions in the primary care setting. There are many successful programs throughout the country and a developing program at MUSC.
Learning Objectives:
1. Explain the benefits of collaborative care and the evidence-based model of treating behavioral health conditions in the primary care setting.
2. Describe the current state of the Medical University of South Carolina’s pediatric collaborative care programs.
3. Outline areas for improvement in the current evidence-based model and discuss the future directions of the program.
An Update on Forensic Topics Affecting Youth, Families, and the Community
9:15 AM – 10:15 AM | Nicole Sussman, M.D. | 1.0 CE credit
Synopsis and Learning Objects coming soon
Break
10:15 AM – 10:30 AM
TMS for Treatment of MDD in Adolescent Patients
10:30 AM – 11:30 AM | Ethan Ashley, M.D. | 1.0 CE credit
About the Session: This presentation will present the history/mechanism of action for TMS in treating depression. We will then discuss indications and contraindications for TMS in adolescents, as well as recent FDA approvals and clinical outcomes.
Learning Objectives:
1. Describe the mechanism of action for transcranial magnetic stimulation in the treatment of depression.
2. Discuss the indications, contraindications and criteria needed to utilize TMS in adolescents.
3. Identify recent FDA approved devices for TMS in adolescents.
4. Discuss recent clinical studies/outcomes regarding the efficacy of TMS in treating adolescent depression
ADHD: Critical Consideration in Clinical Management
11:30 AM – 12:30 PM | Rakin Hoq, M.D. | 1.0 CE credit
About the Session: This presentation will provide a brief review of ADHD diagnosis and clinical implications, followed by an overview of critical considerations in symptom evolution, clinical overlap and medication management including nuances of pharmacokinetics in treatment.
Learning Objectives:
1. Define the role Attention Deficit/Hyperactivity Disorder (ADHD) has on patient brain development and core cognitive and emotional functions.
2. Discuss the implications that ADHD has in emotional regulation as well as co-morbidity with other psychiatric illnesses.
3. Explain how to best optimize treatment by utilizing pharmacokinetic nuances of medications to manage ADHD and mitigate the co-morbid risks associated with the diagnosis.
Lunch
12:30 PM – 1:00 PM
Evaluating and Treating Menopause-Associated Insomnia
1:00 PM – 2:00 PM | Suzanne Bertisch, MD, MPH | 1.0 CE credit
Synopsis and Learning Objects coming soon
Transcranial Magnetic Stimulation Clinical and Research Updates in 2026: Harder, Better, Faster, Stronger
2:00 PM – 3:00 PM | Andrew J. Manett, M.D. | 1.0 CE credit
About the Session: Transcranial magnetic stimulation (TMS) is an FDA-approved treatment for Major Depressive Disorder, Obsessive Compulsive Disorder, and Smoking Cessation. TMS has become more accessible to patients over time, however there remain barriers that prevent many patients from being able to receive treatment, including insurance coverage and logistical considerations. This presentation will review existing clinical applications of TMS, as well as recent trials and pre-publication investigations that may help to bring TMS to a wider population of patients.
Learning Objectives:
1. Define the current clinical applications, FDA-approved indications, and insurance coverage for transcranial magnetic stimulation (TMS).
2. Identify the current barriers to treatment, including parameters of various TMS treatment courses, and how clinic locations and number of treatment visits can impact viability of treatment for many patients.
3. Discuss the clinical implications of clinical and research protocols that attempt to shorten treatment course timelines.
Break
3:00 PM – 3:15 PM
Updates in Perinatal Psychiatry
3:15 PM – 4:15 PM | Rubin Aujla, M.D. | 1.0 CE credit
Synopsis and Learning Objects coming soon
Ketamine/Psychedelics (The Effects on Neuroplasticity as it relates to Therapeutic Effects)
4:15 PM – 5:15 PM | Jennifer Jones, M.D. | 1.0 CE credit
Synopsis and Learning Objects coming soon
Day 2 – June 5, 2026
Welcome and Introduction
8:00 AM – 8:15 AM | LalithKumar K. Solai, M.D.
AI and its Potential Applications in Neurocognitive Disorders (NCDs)
8:15 AM – 9:15 AM | Ipsit Vahia, M.D. | 1.0 CE credit
Synopsis and Learning Objects coming soon
Update on Management of Neurocognitive Disorders and the MUSC SCAN Program
9:15 AM – 10:15 AM | Mary Hart Bryan, M.D., Randi Curtiss, M.D., and Nicholas Milano, M.D. | 1.0 CE credit
Synopsis and Learning Objects coming soon
Break
10:15 AM – 10:30 AM
An Update on Alzheimer's Disease: Progress on Diagnosis, Treatment, and Future Directions
10:30 AM – 11:30 AM | Jessica Broadway, M.D. | 1.0 CE credit
About the Session: Will discuss evidence regarding biomarkers for early detection (including serum, plasma, and imaging), as well as current clinical treatment options. Will then discuss current investigational studies (such as AHEAD, Trontier, Alzheimer's Tau Platform, etc.) and any preliminary findings (if available), as wells a future directions.
Learning Objectives:
1. Summarize availability of new treatments for the earliest clinical stages of Alzheimer's disease and required diagnostic and safety monitoring tests.
2. Describe FDA approved diagnostic tools for Alzheimer's disease including Amyloid PET scans and blood based biomarkers, as well as benefits of early pathologic diagnosis.
3. Outline new targets for therapy and disease stages, current/ongoing studies, potential future studies, and highlights of recently concluded studies of investigational drugs in the pipeline for dementia.
End of Life Care
11:30 AM – 12:30 PM | Rindy Fernandes, M.D. | 1.0 CE credit
Synopsis and Learning Objects coming soon
Concluding Remarks
12:30 PM – 12:45 PM | Kevin Gray, M.D.
